Removal of therapeutic anti-lymphocyte antibodies from human sera prior to anti-human leukocyte antibody testing

Journal of Immunological Methods

Volumn 300, Issue 1-2, 2005, Pages 192-199

  Bearden, Christopher M ^a   Book, Benita K ^a   Sidner, Richard A ^a   Pescovitz, Mark D ^a  

^a INDIANA UNIVERSITY   (United States)

Author keywords

Antibodies; Crossmatch; Histocompatibility; Interference; PRA; Transplant

Indexed keywords

FLUORESCEIN ISOTHIOCYANATE; IMMUNOGLOBULIN; LEUKOCYTE ANTIBODY; LYMPHOCYTE ANTIBODY; MONOCLONAL ANTIBODY; OKT 3; RITUXIMAB; THYMOCYTE ANTIBODY;

ANTIBODY LABELING; ARTICLE; CONJUGATION; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOASSAY; IMMUNOLOGICAL PROCEDURES; INCUBATION TIME; NORMAL HUMAN; PRIORITY JOURNAL; SERUM;

ANIMALS; ANTILYMPHOCYTE SERUM; FLOW CYTOMETRY; HUMANS; IMMUNOMAGNETIC SEPARATION; IMMUNOSORBENT TECHNIQUES; LEUKOCYTES; MICE; MUROMONAB-CD3; RABBITS; T-LYMPHOCYTES;

EQUUS CABALLUS; ORYCTOLAGUS CUNICULUS; OVIS ARIES;

EID: 20444406448     PISSN: 00221759     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jim.2005.03.001     Document Type: Article

References (26)

1. D.B. Amos, H. Bashir, W. Boyle, M. MacQueen, and A. Tiilikainen A simple micro cytotoxicity test Transplantation 7 1969 220
2. J.M. Aranda Jr., J.C. Scornik, S.J. Normann, R. Lottenberg, R.S. Schofield, D.F. Pauly, M. Miles, J.A. Hill, J.W. Sleasman, and S. Skoda-Smith Anti-CD20 monoclonal antibody (rituximab) therapy for acute cardiac humoral rejection: a case report Transplantation 73 2002 907
3. C.W. Barlow, M.R. Moon, G.R. Green, P. Gamberg, J. Theodore, B.A. Reitz, and R.C. Robbins Rabbit antithymocyte globulin versus OKT3 induction therapy after heart-lung and lung transplantation: effect on survival, rejection, infection, and obliterative bronchiolitis Transpl. Int. 14 2001 234
4. C.M. Bearden, A. Agarwal, B.K. Book, R.A. Sidner, H.M. Gebel, R.A. Bray, and M.D. Pescovitz Pronase treatment facilitates alloantibody flow cytometric and cytotoxic crossmatching in the presence of rituximab Hum. Immunol. 65 2004 803
5. N. Bonnefoy-Berard, and J.P. Revillard Mechanisms of immunosuppression induced by antithymocyte globulins and OKT3 J. Heart Lung Transplant. 15 1996 435
6. N. Bonnefoy-Berard, C. Vincent, and J.P. Revillard Antibodies against functional leukocyte surface molecules in polyclonal antilymphocyte and antithymocyte globulins Transplantation 51 1991 669
7. N. Bonnefoy-Berard, B. Verrier, C. Vincent, and J.P. Revillard Inhibition of CD25 (IL-2R alpha) expression and T-cell proliferation by polyclonal anti-thymocyte globulins Immunology 77 1992 61
8. R.A. Bray Flow cytometry crossmatching for solid organ transplantation Methods Cell Biol. 41 1994 103
9. D.C. Brennan, K. Flavin, J.A. Lowell, T.K. Howard, S. Shenoy, S. Burgess, S. Dolan, J.M. Kano, M. Mahon, M.A. Schnitzler, R. Woodward, W. Irish, and G.G. Singer A randomized, double-blinded comparison of Thymoglobulin versus Atgam for induction immunosuppressive therapy in adult renal transplant recipients Transplantation 67 1999 1011
10. M. Carrier, G.B. Pelletier, R. Cartier, Y. Leclerc, D. Robitaille, and L.C. Pelletier Induction of immunosuppression with rabbit antithymocyte globulin: five-year experience in cardiac transplantation Can. J. Cardiol. 9 1993 171
11. A.O. Gaber, M.R. First, R.J. Tesi, R.S. Gaston, R. Mendez, L.L. Mulloy, J.A. Light, L.W. Gaber, E. Squiers, R.J. Taylor, J.F. Neylan, R.W. Steiner, S. Knechtle, D.J. Norman, F. Shihab, G. Basadonna, D.C. Brennan, E.E. Hodge, B.D. Kahan, L. Kahan, S. Steinberg, E.S. Woodle, L. Chan, J.M. Ham, and T.J. Schroeder Results of the double-blind, randomized, multicenter, phase III clinical trial of Thymoglobulin versus Atgam in the treatment of acute graft rejection episodes after renal transplantation Transplantation 66 1998 29
12. R.D. Guttmann, P. Caudrelier, G. Alberici, and J.L. Touraine Pharmacokinetics, foreign protein immune response, cytokine release, and lymphocyte subsets in patients receiving thymoglobuline and immunosuppression Transplant. Proc. 29 1997 24S
13. M.L. Henry, R.P. Pelletier, E.A. Elkhammas, G.L. Bumgardner, E.A. Davies, and R.M. Ferguson A randomized prospective trial of OKT3 induction in the current immunosuppression era Clin. Transplant. 15 2001 410
14. K. Hopkins The basic lymphocyte microcytotoxicity tests: standard and AHG enhancement A. Hahn G. Land R. Strothman ASHI Laboratory Manual American Society for Histocompatibility and Immunogenetics vol. 1 2000 1.C.1 1
15. C. Lyonnais, K. Campbell, H. Smith, R. Buelow, T. Schroeder, D. Womble, and J. Regan ATGAM™ levels in kidney transplant patients treated for acute rejection Transplantation 1 1998 139
16. D.G. Maloney Mechanism of action of rituximab Anti-Cancer Drugs 12 2001 S1
17. L. Osowski, and D. Fitzpatrick Depletion of OKT3 from serum A. Hahn G. Land R. Strothman ASHI Laboratory Manual American Societry for Histocompatability and Immunogenetics vol. 4th 2000 I.B.5.1
18. R. Pei, J.H. Lee, N.J. Shih, M. Chen, and P.I. Terasaki Single human leukocyte antigen flow cytometry beads for accurate identification of human leukocyte antigen antibody specificities Transplantation 75 2003 43
19. P. Piascik New therapeutic monoclonal antibodies target kidney transplant rejection and cancer J. Am. Pharm. Assoc. 38 1998 379
20. J. Prazak, J. Hrabanek, and P. Korinkova Rabbit anti-thymocyte globulin, the cause of false-positive results in the microlymphocytotoxicity test? Cas. Lek. Ces. 128 1989 90
21. J.F. Regan, C. Lyonnais, K. Campbell, L.V. Smith, R. Buelow Group, U. S. T. M.-C. S. Total and active thymoglobulin levels: effects of dose and sensitization on serum concentrations Transpl. Immunol. 9 2001 29
22. T. Sawada, T. Ando, S. Sato, K. Kubota, S. Fuchinoue, and S. Teraoka Immunization by blood-type antigen in human immunoglobulin products before ABO-incompatible kidney transplantation Clin. Transplant. 18 2004 219
23. T.J. Schroeder, L.W. Moore, L.W. Gaber, A.O. Gaber, and M.R. First The US multicenter double-blind, randomized, phase III trial of thymoglobulin versus atgam in the treatment of acute graft rejection episodes following renal transplantation: rationale for study design Transplant. Proc. 31 1999 1S
24. D.L. Stippel, W. Arns, M. Pollok, K.T. Beckurts, U.J. Hesse, and A.H. Holscher ALG versus OKT3 for treatment of steroid-resistant rejection in renal transplantation: ten-year follow-up results of a randomized trial Transplant. Proc. 34 2002 2201
25. G. Tyden, G. Kumlien, and I. Fehrman Successful ABO-incompatible kidney transplantations without splenectomy using antigen-specific immunoadsorption and rituximab Transplantation 76 2003 730
26. C.A. Vierra, A. Agarwal, B. Book, R.A. Sidner, C.M. Bearden, H. Gebel, A. Roggero, N. Fineberg, T. Taber, M. Kraus, and M.D. Pescovitz Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: single dose safety and tolerability study Transplantation 77 2004 542